Compare Novo Nordisk A/S (NVO) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares Silver Trust — how do they compare? Novo Nordisk A/S trades at $46.21 (market cap $207.85B), while iShares Silver Trust trades at $59.44. The key difference: Novo Nordisk A/S pays a 3.81% dividend while iShares Silver Trust pays none. Which is the better fit depends on your goals.
| NVO | SLV | |
|---|---|---|
Market Cap | $207.85B | — |
Sector | Health | — |
52-Week High | $63.98 | $105.57 |
52-Week Low | $35.29 | $33.89 |
Enterprise Value | $222.55B | — |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
SLV trades at $59.45, showing minimal daily movement with a 0.07% gain. The technical outlook is bullish with strong moving average support, though RSI levels suggest potential overbought conditions near-term. Recent news highlights silver's rebound driven by data center demand and Fed policy expectations, with the metal recovering from earlier 2026 declines.
Silver's investment case remains compelling due to structural supply constraints and growing industrial demand, particularly from technology sectors. Key risks include Federal Reserve policy uncertainty and dollar strength, while technical resistance near $60 presents immediate price challenges. The metal's volatility requires careful position sizing despite positive long-term fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
